Public health value of fixed‐dose combinations in hypertension

Abstract

It is well documented that reducing blood pressure (BP) in hypertensive individuals reduces the risk of cardiovascular (CV) events. Despite this, many patients with hypertension remain untreated or inadequately treated, and fail to reach the recommended BP goals. Suboptimal BP control, whilst arising from multiple causes, is often due to poor patient compliance and/or persistence, and results in a significant health and economic burden on society. The use of fixed‐dose combinations (FDCs) for the treatment of hypertension has the potential to increase patient compliance and persistence. When compared with antihypertensive monotherapies, FDCs may also offer equivalent or better efficacy, and the same or improved tolerability. As a result, FDCs have the potential to reduce both the CV event rates and the non‐drug healthcare costs associated with hypertension. When FDCs are adopted for the treatment of hypertension, issues relating to co‐payment, formulary restrictions and therapeutic reference pricing must be addressed.

• Compliance
• fixed‐dose combination
• health economics
• hypertension
• persistence
• reimbursement